Search - tctmd.com

Displaying 161 - 180 of 185

Sort: Relevancy | Date

Presentation TCT Russia 2012

DES in 2012 Lessons learned about safety and efficacy

Presenter: Gregg W. Stone

May 28, 2012

Presentation TCT Russia 2012

DES in Complex Multivessel Disease

Presenter: Gregg W. Stone

May 28, 2012

Presentation TCT Russia 2012

Lessons from Pooled Data with Xience Everolimus-Eluting Stents

Presenter: Gregg W. Stone

April 26, 2012

News Daily News

Meta-Analysis: First-Gen DES Show Long-term Safety, Efficacy in STEMI Setting

L.A. McKeown

April 25, 2012

News Daily News

Meta Análisis: Los SLF de 1ª Generación se Muestran Seguros y Eficaces a Largo Plazo contra los STEMI

L.A. McKeown

April 25, 2012

Presentation Fellows 2012

Everolimus-Eluting Stents: Preclinical Foundation and Clinical Results

Presenter: Gregg Stone

April 21, 2012

Presentation ACC 2012

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

Presenter: Gregg Stone

March 28, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

Presentation PCI Outcomes 2012

Controversy 1: Current Drug-Eluting Stents Are Not Only More Effective But Are Safer Than Bare Metal Stents and Should Be Used in more than 90% of (Stented) Patients

Presenter: Gregg W. Stone

March 23, 2012

Presentation

New Drug-eluting Stent Designs: Are Improved Clinical Outcomes Possible?

Presenter: Gregg W. Stone

March 06, 2012

Presentation CTO 2012

The Spectrum of Two-Stent Techniques (and How to Choose)

Presenter: Gregg Stone

February 22, 2012

News Daily News

SCAAR: Second-Generation DES Improve Hard Outcomes

Yael L. Maxwell

January 08, 2012

Presentation TCT 2012

Platinum Chromium Everolimus-Eluting Stent in Long Coronary Lesions.

Presenter: Paul S. Teirstein, Gregg W. Stone, Ian T. Meredith, Tift Mann, Vincent J. Pompili, Louis A. Cannon, Michael R. Mooney, Shigeru Saito, Dominic J. Allocco, Keith D. Dawkins

January 03, 2012

News Daily News

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

L.A. McKeown

August 19, 2011

News Daily News

HORIZONS-AMI Published: Bivalirudin, Taxus Stay Strong at 3 Years

Jason Kahn

June 13, 2011

News Daily News

EES Show Long-term Safety Advantage over SES

L.A. McKeown

May 24, 2011

News Daily News

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

April 20, 2011

News Conference News

PRECOMBAT: PCI with Sirolimus Stent Equivalent to CABG in Left Main Disease

April 05, 2011

News Conference News

PLATINUM: Novel Platinum-Chromium DES Equals Outcomes of Xience V-Promus

L.A. McKeown

April 05, 2011

Advertisement

DES in 2012 Lessons learned about safety and efficacy

DES in Complex Multivessel Disease

Lessons from Pooled Data with Xience Everolimus-Eluting Stents

Meta-Analysis: First-Gen DES Show Long-term Safety, Efficacy in STEMI Setting

Meta Análisis: Los SLF de 1ª Generación se Muestran Seguros y Eficaces a Largo Plazo contra los STEMI

Everolimus-Eluting Stents: Preclinical Foundation and Clinical Results

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Controversy 1: Current Drug-Eluting Stents Are Not Only More Effective But Are Safer Than Bare Metal Stents and Should Be Used in more than 90% of (Stented) Patients

New Drug-eluting Stent Designs: Are Improved Clinical Outcomes Possible?

The Spectrum of Two-Stent Techniques (and How to Choose)

SCAAR: Second-Generation DES Improve Hard Outcomes

Platinum Chromium Everolimus-Eluting Stent in Long Coronary Lesions.

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

HORIZONS-AMI Published: Bivalirudin, Taxus Stay Strong at 3 Years

EES Show Long-term Safety Advantage over SES

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

PRECOMBAT: PCI with Sirolimus Stent Equivalent to CABG in Left Main Disease

PLATINUM: Novel Platinum-Chromium DES Equals Outcomes of Xience V-Promus

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content